

TrubloodTM
the no-risk biopsy



Glioma



DATAR
CANCER GENETICS
UNITED KINGDOM | GERMANY | INDIA

A simple blood draw can aid diagnosis of brain tumors.



About

Trublood™ - Glioma is a prescription blood test that can help diagnose glial malignancies (a type of brain tumor) based on detection of Circulating Glial Cells (CGCs) in a blood sample.



Who can Benefit

Trublood™ - Glioma may be beneficial for:

- ▶ Patients suspected with glial malignancies, who have been advised tissue sampling for diagnosis,
- ▶ As above, but in whom tissue biopsy is not possible, or tissue diagnosis has been inconclusive or is inconsistent with clinical observations,
- ▶ Patients who have been previously diagnosed and treated for glial malignancies with suspected recurrence.



Why Trublood™ - Glioma

Diagnosis of glial malignancies in suspected patients is based on histopathology evaluation (HPE) of tissue samples obtained by surgery or biopsy. Trublood™ - Glioma has a high (>99%) accuracy for detecting glial malignancies and differentiating it from benign glial tumors or non-glial malignancies. Trublood™ - Glioma provides evidence of the presence of CGCs and facilitates a more effective diagnosis of glial malignancies in suspected cases.



How Trublood™ - Glioma Works

Glial malignancies release Circulating Glial Cells (CGCs) into the blood. These CGCs are not detected in patients without glial malignancies or those with benign conditions. Trublood™ - Glioma analyzes blood samples for the presence of CGCs. Where CGCs are detected, this information is used by the physician along with other clinical findings and assessments to arrive at a diagnosis and/or to make appropriate decisions on further clinical management. For those with negative test results, the treating physician will determine the appropriate follow-up.



Sample Collection and Report

Trublood™ - Glioma involves peripheral blood collection which is safe and risk-free. Blood collection can be done at any primary healthcare center or a doctor's office. In several countries, the blood sample collection is possible in the privacy and comfort of the patient's own home. The test does not require a visit to a specialized center nor does it involve long waiting times. The test report will be available in 10-12 working days.



Technology

The technology that powers Trublood™ - Glioma has been developed and stringently validated based on the analysis of blood samples from cancer patients, patients with non-cancerous conditions, and healthy (cancer-free) individuals in large clinical studies. The test is performed by qualified and trained scientists using the most advanced technologies and each report is reviewed by qualified doctors before release. The processing is conducted at accredited laboratories which meet international standards.



Precautions

Trublood™ - Glioma is a 'Prescription Use Only' test; it must be prescribed by a qualified and licensed physician. Trublood™ - Glioma findings must be interpreted and used by a qualified and licensed physician along with other relevant clinical parameters and investigations.

DATAR CANCER GENETICS

UNITED KINGDOM | GERMANY | INDIA

Accreditations for Our Lab in India



Advena Ltd. Tower Business Centre, 2nd Flr.,
Tower Street, Swatar, BKR 4013, Malta

Contact us:

✉ **UK:** enquiries@datarpgx.com • **Germany:** info-eu@datarpgx.com • **India:** response@datarpgx.com

🌐 datarpgx.com

Proprietary Technology, All Intellectual Property Rights Protected under relevant laws.